Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23976834 | 0.86 | MBOAT4 (0.32) | — | |
| SCHEMBL31523105 | 0.79 | MBOAT4 (0.30) | — | |
| SCHEMBL27223422 | 0.73 | — | — | |
| SCHEMBL27379531 | 0.73 | — | — | |
| SCHEMBL21224525 | 0.73 | ALOX5AP (0.31) | GAA | |
| SCHEMBL29421579 | 0.73 | ALOX5AP (0.31) | GAA | |
| SCHEMBL30821200 | 0.73 | — | — | |
| SCHEMBL28204877 | 0.72 | MBOAT4 (0.32) | — | |
| SCHEMBL27223148 | 0.71 | — | — | |
| SCHEMBL22866556 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4729508-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | Arcus Biosciences, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20250214930-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | ARCUS BIOSCIENCES, INC. (US) | 2025-07-03 | — | — | US | disclosed |
| CN-119118872-A | Tetrahydronaphthalene and tetrahydroquinoline compounds as HIF-2 alpha inhibitors | 艾库斯生物科学有限公司 | 2024-12-13 | — | — | CN | disclosed |
| US-12103907-B2 | Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha | ARCUS BIOSCIENCES, INC. (US) | 2024-10-01 | — | — | US | disclosed |
| CN-115298165-B | Tetrahydronaphthalene and tetrahydroquinoline compounds as HIF-2 alpha inhibitors | 艾库斯生物科学有限公司 | 2024-09-17 | — | — | CN | disclosed |
| US-20240254079-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | ARCUS BIOSCIENCES, INC. | 2024-08-01 | — | — | US | disclosed |
| US-11787762-B2 | Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha | ARCUS BIOSCIENCES, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787762-B2 | Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha | ARCUS BIOSCIENCES, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230021476-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | ARCUS BIOSCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
| EP-4121409-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | Arcus Biosciences, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| CN-115298165-A | Tetralin and tetrahydroquinoline compounds as HIF-2 alpha inhibitors | 艾库斯生物科学有限公司 | 2022-11-04 | — | — | CN | disclosed |
| US-11407712-B2 | Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2α | ARCUS BIOSCIENCES, INC. (US) | 2022-08-09 | — | — | US | disclosed |
| US-20210317079-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | ARCUS BIOSCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
| WO-2021188769-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | ARCUS BIOSCIENCES, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| WO-2021188769-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | ARCUS BIOSCIENCES, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214930-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | HIF1AN, HIF1A, EGLN2 | GAA 1620/4885 |
| US-20240254079-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | HIF1AN, HIF1A, EGLN2 | GAA 1620/4885 |
| US-11787762-B2 | Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha | HIF1AN, HIF1A, EGLN2 | GAA 1620/4885 |
| US-20230021476-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | HIF1AN, HIF1A, EGLN2 | GAA 1620/4885 |
| US-11407712-B2 | Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2α | HIF1AN, HIF1A, EGLN2 | GAA 1855/4885 |
| US-12103907-B2 | Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha | HIF1AN, HIF1A, EGLN2 | GAA 1620/4885 |
| US-20210317079-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | HIF1AN, HIF1A, EGLN2 | GAA 1620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.